The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for pharmaceutical pipeline drugs anticipated to be available for utilization within the next fiscal year. Specifically, it mandates the identification of these drugs and their expected costs, which for the upcoming period from April 1, 2026, to March 31, 2027, is estimated to be around $20 million for all MassHealth members, including those in managed care. This report is part of the ongoing effort to monitor and manage healthcare expenditures related to new pharmaceutical entries. In the latest report, the Executive Office has identified 85 pipeline market entries from manufacturers, an increase from the previous report which noted 71 entries. The primary contributors to the projected spending continue to be high-cost cell and gene therapies. Additionally, the bill includes a new contact email for inquiries related to the report, which is Sarah.Nordberg@mass.gov.